SkylineDx and Mayo Clinic To Collaborate on Development of Diagnostic Tests for Melanoma

SkylineDx  and Mayo Clinic are working together to develop novel diagnostic tests which will improve clinical decision making for melanoma patients.

SkylineDx will help Mayo Clinic to optimize and further develop an algorithm to identify risk factors associated with metastasis, originally discovered and developed by Mayo Clinic dermatologist Alexander Meves, M.D., and his team.

The outcome of these molecular-based tests will help physicians target patients to appropriate treatment interventions. This meets the growing need for individual treatment and personalized medicine. Molecular testing can be performed on routinely collected biopsy tissue to determine the probability for metastatic spread with high accuracy.

"The collaboration with Mayo Clinic is a significant achievement for SkylineDx since this enables us to further extend our product offering by using our knowledge and experience in the field of bio-informatics in other disease areas outside of multiple myeloma, building upon our existing assets and capabilities," says Dharminder S. Chahal, Chief Executive Officer of SkylineDx, in a news release. "We are very impressed with the work of Dr. Meves and his group and are delighted that they chose SkylineDx as their collaboration partner to address an unmet medical need and to improve the quality of life for patients."

The basis for this collaboration originated from the data and algorithm published in the peer-reviewed Journal of Clinical Oncology in 2015, in which Dr. Meves and his group worked to discover new molecular risk factors associated with sentinel lymph node (SLN) positivity in the primary melanoma.

Dr. Meves will present new data at the 2018 American Academy of Dermatology Annual Meeting in San Diego, CA, February 16-20, 2018.